Accel Wealth Management increases its equity position in Johnson & Johnson (NYSE:JNJ)


Accel Wealth Management increased its position in Johnson & Johnson shares (NYSE:JNJGet a rating) by 2.0% in Q1, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor held 4,330 shares of the company after acquiring an additional 85 shares during the period. Accel Wealth Management’s holdings in Johnson & Johnson were worth $771,000 when it last filed with the SEC.

Several other hedge funds have also recently bought and sold shares of JNJ. Family CFO Inc purchased a new position at Johnson & Johnson in Q4 worth approximately $26,000. Steward Financial Group LLC bought a new position in Johnson & Johnson in Q4 worth around $34,000. Joseph P. Lucia & Associates LLC bought a new position in Johnson & Johnson in Q1 worth approximately $38,000. Advocacy Wealth Management Services LLC increased its stake in Johnson & Johnson by 41.4% in the 1st quarter. Advocacy Wealth Management Services LLC now owns 229 shares of the company worth $41,000 after buying 67 additional shares last quarter. Finally, Gibson Wealth Advisors LLC bought a new position in Johnson & Johnson in Q4 worth approximately $49,000. Hedge funds and other institutional investors own 68.78% of the company’s shares.

Johnson & Johnson trades up 0.5%

NYSE:JNJ opened at $172.12 on Friday. The company has a fifty-day moving average of $176.25 and a 200-day moving average of $174.36. Johnson & Johnson has a 52-week low of $155.72 and a 52-week high of $186.69. The company has a quick ratio of 1.14, a current ratio of 1.39 and a debt ratio of 0.39. The company has a market capitalization of $452.92 billion, a P/E ratio of 25.05, a P/E/G ratio of 3.48 and a beta of 0.63.

Johnson & Johnson (NYSE:JNJGet a rating) last released its quarterly results on Tuesday, July 19. The company reported EPS of $2.59 for the quarter, beating consensus analyst estimates of $2.57 by $0.02. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.56%. The company posted revenue of $24.02 billion in the quarter, versus analyst estimates of $23.85 billion. During the same period a year earlier, the company posted EPS of $2.48. The company’s revenues increased by 3.0% compared to the same quarter last year. On average, research analysts predict that Johnson & Johnson will post earnings per share of 10.05 for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 6. Shareholders of record on Tuesday, August 23 will receive a dividend of $1.13. The ex-dividend date is Monday, August 22. This represents an annualized dividend of $4.52 and a yield of 2.63%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 65.79%.

Changes to analyst ratings

A number of stock analysts have commented on the stock. Daiwa Capital Markets began covering Johnson & Johnson shares in a Wednesday June 22 research note. They gave the company an “outperform” rating. Wells Fargo & Company raised its price target on Johnson & Johnson stock from $190.00 to $195.00 and gave the stock an “overweight” rating in a Wednesday, July 13 report. Credit Suisse Group raised its price target on Johnson & Johnson shares from $200.00 to $205.00 and gave the stock an “outperform” rating in a Wednesday, April 20 report. Raymond James raised his price target on Johnson & Johnson shares from $195.00 to $196.00 and gave the stock an “outperform” rating in a Wednesday, April 20 report. Finally, UBS Group lowered its price target on Johnson & Johnson shares from $185.00 to $180.00 in a report on Thursday. Four analysts gave the stock a hold rating, six gave the company a buy rating and one gave the company a strong buy rating. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $189.89.

Insiders place their bets

In other news from Johnson & Johnson, CAD Robert J. Decker sold 8,462 shares of the company in a trade on Thursday, May 26. The shares were sold at an average price of $180.00, for a total value of $1,523,160.00. Following completion of the transaction, the chief accounting officer now directly owns 15,473 shares of the company, valued at approximately $2,785,140. The sale was disclosed in a document filed with the Securities & Exchange Commission, accessible via the SEC website. In other Johnson & Johnson news, CAO Robert J. Decker sold 8,462 shares of the company in a trade Thursday, May 26. The shares were sold at an average price of $180.00, for a total value of $1,523,160.00. Following completion of the transaction, the chief accounting officer now directly owns 15,473 shares of the company, valued at approximately $2,785,140. The sale was disclosed in a document filed with the Securities & Exchange Commission, accessible via the SEC website. Also, VPE Kathryn E. Wengel sold 40,000 shares of the company in a trade on Friday, June 10. The stock was sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the completion of the transaction, the executive vice president now owns 71,311 shares of the company, valued at $12,336,803. Disclosure of this sale can be found here. Insiders of the company own 0.35% of the shares of the company.

About Johnson & Johnson

(Get a rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures and sells various healthcare products worldwide. The Company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the brands AVEENO, CLEAN & CLEAR, DR.

Featured Articles

Want to see what other hedge funds hold JNJ? Visit HoldingsChannel.com for the latest 13F filings and insider trading for Johnson & Johnson (NYSE:JNJGet a rating).

Institutional ownership by quarter for Johnson & Johnson (NYSE: JNJ)



Get news and reviews for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily newsletter.

Comments are closed.